PFSA · Profusa, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $100.0K | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $1.61M | - | - | - | - |
| SG&A | $2.99M | - | - | - | - |
| Total Operating Expenses | $4.60M | $1.35M | $1.51M | $1.27M | - |
| D&A | - | - | - | - | - |
| Operating Income | ($27.71M) | ($1.35M) | ($1.51M) | ($1.27M) | - |
| Interest Expense | $4.42M | - | - | - | - |
| Income Tax | - | $80.5K | $456.8K | $499.2K | - |
| Net Income | ($35.82M) | ($8.71M) | $1.16M | $7.17M | - |
| EPS - Basic | ($107.01) | ($1.47) | $0.12 | $0.30 | - |
| EPS - Diluted | ($107.01) | ($1.47) | $0.12 | $0.30 | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.78M | $16.2K | $193.5K | $193.5K | $741.2K |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $7.34M | - | - | - | - |
| Current Assets | $3.76M | $60.9K | $1.58M | $511.7K | $1.10M |
| Total Assets | $3.77M | $8.39M | $10.88M | $194.74M | $193.06M |
| Current Liabilities | $22.26M | $12.31M | $4.92M | $935.8K | $106.5K |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $30.43M | $13.01M | $5.09M | $1.83M | $7.32M |
| Stockholders' Equity | ($26.66M) | ($12.96M) | ($3.46M) | ($619.5K) | ($5.91M) |
| Retained Earnings | ($160.78M) | ($12.96M) | ($3.46M) | ($620.0K) | ($5.91M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($16.25M) | ($1.30M) | ($2.06M) | ($581.2K) | - |
| Investing Cash Flow | ($2.01M) | $2.97M | $185.60M | $33.4K | - |
| Financing Cash Flow | $19.84M | ($1.66M) | ($183.72M) | - | - |
| CapEx | $8.0K | - | - | - | - |
| Free Cash Flow | ($16.26M) | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -27706.0% | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | -35823.0% | - | - | - | - |
| Free cash flow margin | -16256.0% | - | - | - | - |
| FCF / Net income | 0.45 | - | - | - | - |
| R&D / Revenue | 1608.0% | - | - | - | - |
| SG&A / Revenue | 2992.0% | - | - | - | - |
| Effective tax rate | - | - | 28.2% | 6.5% | - |
| Return on assets | -949.0% | -103.8% | 10.7% | 3.7% | - |
| Return on equity | 134.4% | 67.2% | -33.6% | -1157.1% | - |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 0.17 | 0.00 | 0.32 | 0.55 | 10.31 |
| Quick ratio | 0.17 | 0.00 | 0.32 | 0.55 | 10.31 |
| Cash ratio | 0.08 | 0.00 | 0.04 | 0.21 | 6.96 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -6.3x | - | - | - | - |
| Equity multiplier | -0.14 | -0.65 | -3.15 | -314.36 | -32.67 |
| Liabilities / Assets | 8.06 | 1.55 | 0.47 | 0.01 | 0.04 |
| Efficiency | |||||
| Asset turnover | 0.03 | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -1950.7% | 10.4% | -18.7% | - | - |
| Net income growth (YoY) | -311.2% | - | -83.8% | - | - |
| EPS growth (YoY) | -7179.6% | - | -60.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -105.7% | -274.5% | -458.4% | 89.5% | - |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-62.73
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Profusa against the 5 most active filers in the same SIC group.